Table 3 Clinical outcomes and adverse events
Treatment outcomes | Data |
|---|---|
Treatment success, n (%) | 52 (92.9) |
Surgical intervention for treatment failure (VATS with decortication), n (%) | 2 (3.6) |
30 day mortality due to pleural infection, n (%) | 2 (3.6) |
30 day readmission rate, n (%) | 0 (0) |
Median hospital stay (IQR) | 15 (11–28) |
Median cumulative volume of pleural drainage 24 h after first dose of intrapleural therapy (IQR), mL | 447.5 (177.5–769.75) |
Median cumulative volume of pleural drainage 48 h after first dose of intrapleural therapy (IQR), mL | 995 (520–1445.5) |
Median cumulative volume of pleural drainage 72 h after first dose of intrapleural therapy (IQR), mL | 1470 (717.5–1989.75) |
Median days of chest tube in pleural cavity (IQR) | 10 (7–14) |
Bleeding outcomes | |
|---|---|
Pleural bleeding | 9 (16.1) |
Pleural bleeding requiring ≥ 2U pRBC transfusion | 5 (8.9) |
Gastrointestinal bleeding | 0 (0) |
Intracranial bleeding | 0 (0) |
Other bleeding | 0 (0) |
Mean hemoglobin loss (SD), g/dL | 3.5 (1.1) |
Median units of pRBC transfusion in patients transfused (IQR) | 2 (2–5) |
Surgical intervention for pleural bleeding, n (%) | 3 (5.4) |
30 day mortality due to pleural bleeding, n (%) | 0 (0) |